國立虎尾科技大學 |

Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents/ by Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui.
作者:	Hirakawa, Akihiro.
其他作者:	Sato, Hiroyuki.
面頁冊數:	XIII, 89 p. 3 illus.online resource. :
Contained By:	Springer Nature eBook
標題:	Statistics . -
電子資源:	https://doi.org/10.1007/978-4-431-55573-5
ISBN:	9784431555735

Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents
Hirakawa, Akihiro.

Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents[electronic resource] /by Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui. - 1st ed. 2018. - XIII, 89 p. 3 illus.online resource. - JSS Research Series in Statistics,2364-0057. - JSS Research Series in Statistics,.

1. Introduction -- 2. Phase I Trials for Drug Development in Oncology -- 3. A Summary of Dose -- Finding Methods in Standard Phase I Trials -- 4. Phase I Trials for Combination of Two Agents -- 5. Phase I Trials for Joint Assessment of Both Efficacy and Toxicity -- 6. Additional Topics on Adaptive Dose -- Finding Methods.

This book deals with advanced methods for adaptive phase I dose-finding clinical trials for combination of two agents and molecularly targeted agents (MTAs) in oncology. It provides not only methodological aspects of the dose-finding methods, but also software implementations and practical considerations in applying these complex methods to real cancer clinical trials. Thus, the book aims to furnish researchers in biostatistics and statistical science with a good summary of recent developments of adaptive dose-finding methods as well as providing practitioners in biostatistics and clinical investigators with advanced materials for designing, conducting, monitoring, and analyzing adaptive dose-finding trials. The topics in the book are mainly related to cancer clinical trials, but many of those topics are potentially applicable or can be extended to trials for other diseases. The focus is mainly on model-based dose-finding methods for two kinds of phase I trials. One is clinical trials with combinations of two agents. Development of dose-finding methods for two-agent combination trials requires reasonable models that can adequately capture joint toxicity probabilities for two agents, taking into consideration possible interactions of the two agents on toxicity probability such as synergistic or antagonistic effects. Another is clinical trials for evaluating both efficacy and toxicity outcomes in single- and two-agent combination trials. These methods are often applied to the phase I trials including MTAs because the toxicity and efficacy for a MTA does not monotonically increase with dose, but the efficacy often increases initially with the dose and then plateaus. Successful software implementations for several dose-finding methods are introduced in the book, and their operating characteristics in practice are discussed. Recent advance of the adaptive dose-finding methods in drug developments are also provided.

ISBN: 9784431555735

Standard No.: 10.1007/978-4-431-55573-5doiSubjects--Topical Terms:

1253516
Statistics .

LC Class. No.: QA276-280

Dewey Class. No.: 519.5

Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents
LDR:03732nam a22004095i 4500 001 997678
003 DE-He213
005 20200704025906.0
007 cr nn 008mamaa
008 201225s2018 ja | s |||| 0|eng d
020 $a 9784431555735 $9 978-4-431-55573-5
024 7 $a 10.1007/978-4-431-55573-5 $2 doi
035 $a 978-4-431-55573-5
050 4 $a QA276-280
072 7 $a PBT $2 bicssc
072 7 $a MED090000 $2 bisacsh
072 7 $a PBT $2 thema
072 7 $a MBNS $2 thema
082 0 4 $a 519.5 $2 23
100 1 $a Hirakawa, Akihiro. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1227386
245 1 0 $a Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents $h [electronic resource] / $c by Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui.
250 $a 1st ed. 2018.
264 1 $a Tokyo : $b Springer Japan : $b Imprint: Springer, $c 2018.
300 $a XIII, 89 p. 3 illus. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a JSS Research Series in Statistics, $x 2364-0057
505 0 $a 1. Introduction -- 2. Phase I Trials for Drug Development in Oncology -- 3. A Summary of Dose -- Finding Methods in Standard Phase I Trials -- 4. Phase I Trials for Combination of Two Agents -- 5. Phase I Trials for Joint Assessment of Both Efficacy and Toxicity -- 6. Additional Topics on Adaptive Dose -- Finding Methods.
520 $a This book deals with advanced methods for adaptive phase I dose-finding clinical trials for combination of two agents and molecularly targeted agents (MTAs) in oncology. It provides not only methodological aspects of the dose-finding methods, but also software implementations and practical considerations in applying these complex methods to real cancer clinical trials. Thus, the book aims to furnish researchers in biostatistics and statistical science with a good summary of recent developments of adaptive dose-finding methods as well as providing practitioners in biostatistics and clinical investigators with advanced materials for designing, conducting, monitoring, and analyzing adaptive dose-finding trials. The topics in the book are mainly related to cancer clinical trials, but many of those topics are potentially applicable or can be extended to trials for other diseases. The focus is mainly on model-based dose-finding methods for two kinds of phase I trials. One is clinical trials with combinations of two agents. Development of dose-finding methods for two-agent combination trials requires reasonable models that can adequately capture joint toxicity probabilities for two agents, taking into consideration possible interactions of the two agents on toxicity probability such as synergistic or antagonistic effects. Another is clinical trials for evaluating both efficacy and toxicity outcomes in single- and two-agent combination trials. These methods are often applied to the phase I trials including MTAs because the toxicity and efficacy for a MTA does not monotonically increase with dose, but the efficacy often increases initially with the dose and then plateaus. Successful software implementations for several dose-finding methods are introduced in the book, and their operating characteristics in practice are discussed. Recent advance of the adaptive dose-finding methods in drug developments are also provided.
650 0 $a Statistics . $3 1253516
650 0 $a Biostatistics. $3 783654
650 1 4 $a Statistics for Life Sciences, Medicine, Health Sciences. $3 670172
650 2 4 $a Statistical Theory and Methods. $3 671396
700 1 $a Sato, Hiroyuki. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1289067
700 1 $a Daimon, Takashi. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1227385
700 1 $a Matsui, Shigeyuki. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1172364
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9784431555728
776 0 8 $i Printed edition: $z 9784431555742
830 0 $a JSS Research Series in Statistics, $x 2364-0057 $3 1255493
856 4 0 $u https://doi.org/10.1007/978-4-431-55573-5
912 $a ZDB-2-SMA
912 $a ZDB-2-SXMS
950 $a Mathematics and Statistics (SpringerNature-11649)
950 $a Mathematics and Statistics (R0) (SpringerNature-43713)